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Abstract: Metastatic extramammary Paget’s disease is a rare adenocarcinoma with poor prognosis.
Several reports of human epidermal growth factor receptor 2 alterations point to its pathogenic role
in the disease. However, the occurrence of treatment resistance to anti-HER2 therapy demand the
need for further knowledge. We report of a patient with metastatic penoscrotal extramammary Paget’s
disease, with an ERBB2S310F mutation, in which near complete response was achieved upon treatment
with trastuzumab and carboplatin. However, after 10 cycles of trastuzumab and carboplatin, widespread
metastasis re-occurred. Analysis of a newly developing metastasis revealed additional genomic alterations
including ERBB3A232V and PIK3CAG106V point mutations as well as MET and CDK6 amplification,
providing a potential mechanism of acquired treatment resistance. Therefore, ERBB family inhibitor
afatinib was initiated. Unfortunately, the patient succumbed to disease-related complications shortly after
treatment initiation. This is the first report of ERBB2S310F mutated, metastatic extramammary Paget’s
disease with secondary resistance to trastuzumab / carboplatin, potentially due to additional acquired
genomic alterations. This case contributes to the growing evidence of HER2 in the pathogenesis of
metastatic extramammary Paget’s disease and emphasizes the importance of repetitive, genomic analysis
in rare diseases.
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ABSTRACT
Metastatic extramammary Paget’s disease is a rare adenocarcinoma with poor 
prognosis. Several reports of human epidermal growth factor receptor 2 alterations 
point to its pathogenic role in the disease. However, the occurrence of treatment 
resistance to anti-HER2 therapy demand the need for further knowledge. We report 
of a patient with metastatic penoscrotal extramammary Paget’s disease, with an 
ERBB2S310F mutation, in which near complete response was achieved upon treatment 
with trastuzumab and carboplatin. However, after 10 cycles of trastuzumab and 
carboplatin, widespread metastasis re-occurred. Analysis of a newly developing 
metastasis revealed additional genomic alterations including ERBB3A232V and 
PIK3CAG106V point mutations as well as MET and CDK6 amplification, providing a 
potential mechanism of acquired treatment resistance. Therefore, ERBB family 
inhibitor afatinib was initiated. Unfortunately, the patient succumbed to disease-
related complications shortly after treatment initiation. This is the first report of 
ERBB2S310F mutated, metastatic extramammary Paget’s disease with secondary 
resistance to trastuzumab / carboplatin, potentially due to additional acquired 
genomic alterations. This case contributes to the growing evidence of HER2 in the 
pathogenesis of metastatic extramammary Paget’s disease and emphasizes the 
importance of repetitive, genomic analysis in rare diseases.
INTRODUCTION
Extramammary Paget’s disease (EMPD) is a rare 
intraepithelial adenocarcinoma, localized in apocrine 
gland-rich sites, most commonly perianal, vulvar and 
penoscrotal. The clinical presentation is discreet and 
eczematous in nature, often causing a delay in diagnosis. 
Most cases of EMPD are in-situ and have an excellent 
prognosis. In 5-25%, dermal invasion is visible, 
correlating with a poor prognosis. Due to the rarity of 
the disease, evidence-based management in both in-
situ and metastatic disease is scarce. In the past, various 
combinatorial chemotherapeutic regimens were applied, 
with limited success. Recently, growing evidence suggests 
a central role of human epidermal growth factor receptor 
(HER) 2 in the disease. Yet incomplete responsiveness 
and the occurrence of treatment resistance to anti-HER2 
treatment frequently occurs.
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RESULTS
We report on an 80-year-old patient in excellent 
general condition (ECOG 0), who was referred to our 
clinic for further treatment of a chronic scrotal eczema. 
Upon physical examination, erythematous plaque with 
multiple nodules affecting the skin of the scrotum was 
seen, along with prominent inguinal lymphadenopathy 
(Figure 1A). Histologic analysis showed an ulcerated 
and invasive adenocarcinoma with Paget cells, consistent 
with the diagnosis of extramammary Paget’s disease. 
Furthermore, enlarged and metabolic active inguinal, 
iliacal and interaortocaval lymph-nodes were detectable 
on PET/CT-imaging (Figure 2A). Indeed, fine needle 
aspiration (FNA) confirmed the presence of lymph 
node metastasis. Fluorescence in situ (FISH) for HER2 
amplification was negative and immune-histochemical 
staining for HER2 was 2+, classifying the patient as HER2 
negative, according to current ASCO/CAP Guidelines [1]. 
Urological and gastroenterological examination did 
not reveal underlying malignancy of the prostate or 
gastrointestinal tract, respectively. After interdisciplinary 
discussion, the patient was opted for radiotherapy of the 
penoscrotal region and metabolic active lymph nodes 
(cumulative 60Gy), which was well tolerated.
6 months into follow-up, scrotal inflammation re-
occurred (Figure 1B). Multiple mapping skin biopsies 
revealed apocrine adenocarcinoma in situ. PET/CT imaging 
showed new metabolic activity of the thoracal and retrocrural 
lymph-nodes, and a metabolically active nodulous in the 
superior right lobe of the lung (Figure 2B). FNA of the 
pulmonal nodule confirmed the presence of pulmonary 
metastasis. In order to identify targetable molecular 
alterations, next-generation sequencing (Oncomine Focus 
Assay) of the scrotal tumor was performed, revealing an 
activating ERBB2S310F point mutation. Accordingly lapatinib 
treatment (1250mg daily) was initiated [2]. However, the 
patient’s general condition deteriorated continuously along 
with respiratory insufficiency, leading to the necessity 
of continuous oxygen supplementation. While scrotal 
inflammation worsened, PET/CT imaging showed disease 
progression with pleural effusions and bone metastasis 
(Figure 1C and 2C, respectively). Again, histological 
analysis of FDG-avid bronchial mucosa was performed, 
confirming the presence of Paget-cells. Interestingly, HER2 
immune-histochemical staining was strongly positive 
(3+) classifying the patient as HER2 positive. Therefore, 
lapatinib was discontinued and the patient was treated with 
trastuzumab (6mg/kg body weight) and carboplatin (300mg) 
every 3 weeks. Within one month, the patient’s general 
condition improved rapidly and oxygen supplementation 
was not further needed. In addition, scrotal inflammation 
resolved (Figure 1D). PET/CT imaging showed partial 
response of all lymph node metastasis, as well as subtotal 
response of pulmonary and bone metastasis (Figure 2D). A 
single bone metastasis at the cervical vertebra was irradiated 
due to local disease progression.
After 10 cycles of trastuzumab and carboplatin, 
follow-up PET/CT imaging displayed disease progression, 
with re-occurrence of multiple lymph-node and pulmonary 
metastasis (Figure 2E). Scrotal inflammation was mildly 
increased (Figure 1E). Molecular analysis (Oncomine 
Focus Assay) from a newly developing and metabolic 
active hilar lymph node metastasis was performed. 
Apart from the known ERBB2S310F mutation, additional 
genomic alterations were identified, including ERBB3A232V 
and PIK3CAG106V point mutations, and amplification of 
CDK6. In order to identify further potential treatable 
targets, Foundation One analysis was performed, 
revealing additional, equivocal MET amplification. Given 
the fact, that ERRB3 mutations have been associated 
with resistance to ERBB2 targeted treatment strategies, 
trastuzumab / carboplatin was discontinued and afatinib, 
an ERRB family Inhibitor, was initiated [3]. Unfortunately, 
8 days after initiation of afatinib, the patient died of 
community acquired pneumonia.
DISCUSSION
Advances have been made in the treatment 
of metastatic extramammary Paget’s disease. The 
identification of ERBB2 amplifications and somatic 
mutations in EMPD has enabled disease specific, targeted 
treatment [4]. Indeed, 15-80% of all EMPD patients show 
immune-histochemical HER2 positivity, associated with 
a biologically aggressive phenotype [5]. Accordingly, 
anecdotal anti-HER2 treatment has significantly improved 
the outcome of metastasized EMPD, emphasizing 
its pathogenic role the disease. However, incomplete 
responsiveness and the occurrence of treatment resistance 
Figure 1: Therapeutic efficacy assessed by clinical penoscrotal examination. Imaging of the penoscrotal region (A) at the initial 
presentation, (B) following recurrent disease after radiation therapy (C) after lapatinib treatment (D) best response during trastuzumab and 
carboplatin treatment, and (E) disease progression after 10 cycles of trastuzumab and carboplatin.
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to anti-HER2 therapies demand the need for further 
knowledge.
The tyrosine receptor kinase HER2 causes increased 
MAPK/ERK and PI3K/mTOR pathway signaling, 
accelerating cell growth and survival. Historically, HER2 
status is assessed by immuno-histochemistry (IHC) and 
fluorescence in-situ hybridization (FISH) for the detection 
of overexpression and amplification, respectively. 
However, nonamplified, activating ERBB2-mutations are 
not detected by IHC / FISH. Furthermore, only 30% of all 
ERBB2 alterations are amplifications, and nearly 2% of 
all tumors carry ERBB2 mutations [4, 6]. The activating 
S310F point mutation is the most common somatic 
mutation in ERBB2 and has been successfully targeted 
in EMPD [6, 7]. Given the similar beneficial response 
to anti-HER2 treatment in amplified and non-amplified 
ERBB2 alterations, patients with a potential benefit to anti-
HER2 treatment may not be identified using IHC / FISH.
Here we report on the clinical efficacy of 
trastuzmab / carboplatin in an 80-year-old male patient 
with metastatic penoscrotal EMPD, harboring a somatic 
ERBB2S310F mutation, with primary resistance to lapatinib. 
Upon disease progression, sequential genetic profiling 
revealed additional somatic point mutations in ERBB3 
(p.A232V) and PIK3CA (p.G106V) as well as MET and 
CDK6 amplification. ERBB3A232V is a missense, hot-
spot mutation within the extracellular domain, causing 
anchorage-independent growth and signaling when HER2 
kinase activity is present [3]. Accordingly, in the presence 
of ERBB2S310F, additional somatic ERBB3A232V may have 
caused a compensatory mechanism of resistance to ERBB2 
targeted therapy. Indeed, ERBB3 mutations have been 
shown to cause resistance to ERBB2 targeted therapy [3]. 
PIK3CAG106V is a missense, activating hot-spot mutation 
within the adaptor-binding domain of the catalytic 
subunit of the phosphoinositide 3-kinase, stimulating 
its lipid kinase activity [8]. Activation of downstream 
signaling pathways are a known mechanism of secondary 
resistance and mutations in PIK3CA are associated with 
resistance to trastuzumab [9]. In addition, both MET and 
CDK6 amplification have been described to contribute to 
trastuzumab resistance in HER2-overexpressing breast 
cancer [10, 11].
This is the first description of acquired somatic 
alterations occurring after secondary treatment resistance 
in a patient with non-amplified, ERBB2 mutated, 
metastatic EMPD. Interestingly, these acquired genetic 
alterations may have caused treatment resistance and 
contribute to the understanding of commonly occurring 
secondary treatment failure of anti-HER2 treatments 
in metastatic EMPD. Furthermore, this case provides 
rationale for repetitive genomic analysis in treatment 
resistant EMPD lesions and contributes to the growing 
evidence of ERBB2 in the pathogenesis of metastatic 
extramammary Paget’s disease.
MATERIALS AND METHODS
DNA from FFPE tumor tissue was isolated using 
the automated Maxwell isolation system (Promega). Next 
generation sequencing was performed on formalin-fixed 
paraffin embedded (FFPE) samples, using the Oncomine 
Focus Assay (Life Technologies / Thermo Fisher) and the 
FoundationOne panel. Library preparation and sequencing 
was performed according to the manufacturers’ manuals.
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